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Molecular diagnosticsMitochondrial diseases are notoriously difﬁcult to diagnose due to extreme locus and allelic heterogeneity,
with both nuclear and mitochondrial genomes potentially liable. Using exome sequencing we demonstrate
the ability to rapidly and cost effectively evaluate both the nuclear and mitochondrial genomes to obtain a
molecular diagnosis for four patients with three distinct mitochondrial disorders. One patient was found to
have Leigh syndrome due to a mutation in MT-ATP6, two affected siblings were discovered to be compound
heterozygous for mutations in the NDUFV1 gene, which causes mitochondrial complex I deﬁciency, and one
patient was found to have coenzyme Q10 deﬁciency due to compound heterozygous mutations in COQ2. In all
cases conventional diagnostic testing failed to identify a molecular diagnosis. We suggest that additional
studies should be conducted to evaluate exome sequencing as a primary diagnostic test for mitochondrial
diseases, including those due to mtDNA mutations.
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Disorders of mitochondrial dysfunction, a group of disorders that
display both clinical and genetic heterogeneities, develop as a result
of dysfunction of the mitochondrial respiratory chain and can be
caused by mutations in any of over 900 genes in the nuclear and
mitochondrial genomes [1]. Most mitochondrial diseases involve mul-
tiple organ systems and may present with prominent neurologic and
myopathic phenotypes, some of which can present as life threatening
medical crises. Mitochondrial disorders are commonly classiﬁed as
clinical syndromes based upon characteristic constellations of clinical
features. For example, mitochondrial encephalomyopathy with lactic
acidosis and stroke-like episodes (MELAS, OMIM #540000) is a
separate syndrome from myoclonic epilepsy with ragged-red ﬁbers
(MERRF, #545000). Other kindred conditions are Kearns–Sayre
syndrome (KSS, OMIM #530000), and Leigh syndrome (LS, OMIM
#256000). However, due to signiﬁcant clinical variability many
individuals do not ﬁt perfectly into one particular syndrome. Frequent
features of mitochondrial disease are diabetesmellitus, cardiomyopathy,
proximal myopathy, ptosis, external ophthalmoplegia, sensorineural
deafness, optic atrophy, pigmentary retinopathy and can exhibit central
nervous system manifestations including seizures, encephalopathy,
stroke-like episodes, ataxia, and spasticity.
Mitochondrial disorders may be caused by defects of the mitochon-
drial genome (mtDNA) or nuclear genome. mtDNAmutations are trans-
mitted by maternal inheritance, whereas, nuclear gene mutations may
be inherited in an autosomal recessive, dominant or X-linked manner
[2]. The mitochondrial genome is a circular double stranded DNA of
~16,569 nucleotides that has 37 genes, encoding 13 essential subunits
of the respiratory chain, 22 transfer RNAs, and 2 ribosomal RNAs [3].
Each human cell contains hundreds to thousands of copies of mtDNA.
While most individuals carry identical copies of mtDNA (homoplasmy),
some inherit more than one mtDNA type from their mother
(heteroplasmy) and others may develop heteroplasmy secondary to a
new mutation within the mtDNA. The ratio of heteroplasmic mtDNA
types can vary among individuals within the same maternal lineage,
and also among organs and tissues within the same individual [4]. At
least 77 nuclear genes have been linked to mitochondrial diseases, but
over 1000 genes are implicated in mitochondrial function, many of
which may also cause clinical manifestations if defective [5]. Overall, a
conservative estimate for the prevalence of all mitochondrial diseases
is 1 in 5000 live births [6].
Given the clinical variability and large number of both nuclear and
mitochondrial genes in which mutations can occur and result in
disease make speciﬁc diagnoses of mitochondrial diseases at the
molecular level challenging. Any possible inheritance pattern is possi-
ble, including autosomal dominant, recessive, X-linked, mitochondrial
(maternal) or sporadic. In addition, there is pleiotropy, with the same
mutation potentially exhibiting diverse phenotypes in different indi-
viduals, even within the same family. An ideal test for mitochondrial
disease would include testing both the nuclear and mitochondrial
genomes concurrently. The American College of Medical Genetics and
Genomics recently released a policy statement that stated wholeexome and genome sequencing should be considered in the clinical di-
agnostic assessment of patients when the disorder has a high degree of
genetic heterogeneity [7]. Clearly, mitochondrial diseases ﬁt this
description. Accordingly, we report the use of exome sequencing
using a commercially available exome kit without speciﬁc enrichment
or ampliﬁcation of the mtDNA to deﬁnitively diagnose one patient
with Leigh syndrome (LS, OMIM #256000), two siblings with mito-
chondrial complex I deﬁciency (OMIM #252010), and one patient
with coenzyme Q10 deﬁciency (OMIM #607426). In each of the cases
presented herein, conventional molecular testing had failed to produce
a molecular diagnosis. Furthermore, we demonstrate the ability to
detect both homoplasmic and heteroplasmic variants in the mitochon-
drial genome from exome sequencing without speciﬁcally targeting
the mtDNA.
2. Case presentations
2.1. CMH000067
The ﬁrst case was a three year old female who was born to a
35-year-old female at 38.5 week gestation via spontaneous vaginal
delivery. Pregnancy and delivery were uncomplicated. Maternal
serum screening was reportedly normal and an amniocentesis was
declined. A level II ultrasound was performed and was reportedly
normal. Family history was unremarkable and there is no known
consanguinity. Growth parameters were appropriate for gestational
age with a birth weight of 2580 g (approximately 5th percentile)
and length of 48.26 cm (between the 10th and 25th percentiles).
She passed her newborn hearing screen and was discharged from
the hospital after two days. Shortly thereafter she was noted to
have feeding difﬁculties due to a poor suck. She breast fed for two
weeks, but had poor weight gain, requiring supplementation with
formula. Breastfeeding was discontinued by six weeks of age; howev-
er, the infant continued to have difﬁculties with choking and irritabil-
ity after eating. Anti-reﬂux medication was started at six months of
age and used intermittently until nine months of age. At nine months
of age the parents expressed concern over her development because
she was not sitting unsupported. This child displayed severe growth
retardation in weight, height and head circumference. A brain mag-
netic resonance imaging (MRI) study was conducted at 17 months
of age, demonstrating symmetric high T2 signal and restricted diffu-
sion in the bilateral caudate heads and putamen and double lactic
peaks on magnetic resonance spectroscopy (MRS). These ﬁndings
were considered nonspeciﬁc but consistent with a possible mitochon-
drial disorder. Other diagnostic considerations included a multitude
of metabolic disorders or acute disseminated encephalomyelitis. At
20 months she was reevaluated by a geneticist and found to be able
to stand and bear weight for about 30 s before falling down due to
fatigue. Upon physical examination, she was noted to be the 10th per-
centile for weight, 5th percentile for height and 10–25th percentile
for head circumference (Fig. 1). Other ﬁndings included soft, doughy
skin and hypotonia (Fig. 1) with a normal response to tuning fork. Lab
testing revealed elevated levels of lactic acid (3.0 mmol/L; reference
Fig. 1. Image of CMH000067.
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range 0.08–0.16 mmol/L), with a lactic acid to pyruvate ratio of 13.6
(normal is less than 20) and slight elevation of alanine (595 mcmol/L,
reference range 143–439 mcmol/L) on her plasma amino acid proﬁle
suggestive of a disorder of energy metabolism. Multiple genetic tests
for mitochondrial myopathies were unrevealing, including chromo-
some analysis (46, XX), arrayCGH microarray analysis, mitochondrial
DNA sequencing for common tRNA mutations, as well as a
next-generation sequencing panel for 24 nuclear genes for mitochon-
drial diseases performed at GeneDx (Supplement Table 1). Due to the
numerous negative genetic tests previously conducted, and the large
number of potential candidate genes remaining for a potential mito-
chondrial disorder, exome sequencing was considered the most
cost-effective approach likely to reveal a causal mutation. At the time
of enrollment in our study, at age three, severe growth retardation
was still noted; weight was 11.7 kg (5th percentile), height was
89.1 cm (10th percentile), and head circumference was 45 cm (b2nd
percentile), respectively.
2.2. CMH000254 & CMH000255
The female proband, CMH000254, was the product of a second
pregnancy to a 21 year old female and 26 year male. At birth she was
2835 g (10th percentile) for weight and, 47.5 cm (14th percentile)
for height. The pregnancy was complicated by tobacco exposure and
hypertension that did not require medical treatment. Fetal movements
were described as normal. Maternal serum screening and prenatal ul-
trasounds were without abnormality. The family history was remark-
able for a male sibling, CMH000255, who died on day of life 3 with
an undeﬁned disorder associated with metabolic acidosis. The proband
was born at 39 weeks by repeat Cesarean section and was found to beacidotic soon after birth. She was transferred from a local hospital to a
regional hospital at 9 h of life, and to a tertiary care hospital at by 18 h
of life for management of metabolic acidosis. Initial labs revealed an
ammonia level of 29 mcmol/L (reference range 15–92 mcmol/L) and
a lactic acid level of 11.9 mmol/L (reference range 0.7–2.1 mmol/L).
Physical examination was remarkable for an average for gestational
age infant female who was nondysmorphic but relatively edematous
who responded slowly to stimulation. She appeared symmetric and
proportionate. Her cranium was well shaped without frontal bossing.
The fontanelles were open and somewhat wide, particularly the
coronal and metopic sutures. There was periorbital edema but eye
exam was otherwise unremarkable. No corneal clouding, cataracts or
colobomata were appreciated. Ears were somewhat lowset but other-
wise normal. Nasal tip was upturned. Palate was intact. Other pertinent
ﬁndings included a somewhat deep sacral crease without dimpling,
hair tufts or draining, a liver edge that was palpable at the right costal
margin, normal external female genitalia, no limb length anomalies,
somewhat redundant skin on the hands with deep creases and loose
joints. Neurologic examination was remarkable for diffuse hypotonia,
withdrawal response to stimuli without eye opening, biting rather
than sucking oral movements and diminished Moro reﬂex without
cry. An echocardiogram revealed a 3 mm patent ductus arteriosis
with right to left ﬂow during systole and left to right ﬂow during dias-
tole, suggestive of suprasystemic pulmonary artery pressure. The right
ventricle wasmildly dilatedwithmild tomoderately depressed systolic
function and there was moderate tricuspid regurgitation. There was a
small secundum atrial septal defect versus a patent foramen ovale.
Left ventricular systolic function was adequate. A head ultrasound
revealed diffusely abnormal echogenicity throughout the brain and
cerebellar parenchyma with diminished gray-white matter differentia-
tion suggestive of cerebral edema. Bilateral intraventricular cysts or
synechiae were also appreciated. A renal ultrasound was without
abnormalities. Laboratory studies were remarkable for a sodium
of 142 mmol/L (132–142 mmol/L), a potassium of 3.9 mmol/L (3.5–
6.2 mmol/L), a chloride of 105 mmol/L (99–112 mmol/L), carbon diox-
ide of 7 mmol/L (18–29 mmol/L), an anion gap of 30 mmol/L
(7–14 mmol/L), a calcium of 9.5 mg/dL (8.6–11.0 mg/dL) and glucose
of 69 mg/dL. Blood urea nitrogen was not elevated at 3 mg/dL
(5–20 mg/dL); however, creatinine was elevated at 0.77 mg/dL
(0.06–0.64 mg/dL). Liver function tests were essentially normal as
was a complete blood count. Notably, the infant was acidotic without
signiﬁcant response to bicarbonate with an initial arterial blood gas
upon arrival with a pH of 7.25, a pCO2 of 64, a pO2 of 64 and a HCO3
of 9 with a base excess of −18.2. A lactic acid level was 24.7 mmol/L
(0.7–2.1 mol/L) with a beta-hydroxybutyric acid level of 555.2
(0–269 mcmol/L) and an ammonia level of 25 (15–92 mcmol/L).
Lactic acid levels were followed sequentially and never decreased
below 24.3 mmol/L. A lactic to pyruvic acid ratio was not initially avail-
able. Given the worsening of the lactic acid levels on dextrose and the
concern about a possible defect of pyruvate catabolism in light of a
metabolic acidosis without signiﬁcant ketosis, lactic acidemia and
normoglycemia, dextrose was removed from the IV ﬂuids and riboﬂa-
vin, biotin and carnitine were started. The differential diagnosis includ-
ed disorders of pyruvate catabolism (pyruvate dehydrogenase complex
deﬁciency, pyruvate carboxylase deﬁciency) or a mitochondrial
disease. While organic acidemias such as methylmalonic acidemia or
propionic acidemia were considered, the clinical presentation without
hyperammonemia was less consistent with such a disorder. The infant
eventually required ventilatory support and had worsening of her lac-
tic acidemia and metabolic acidosis despite provision of bicarbonate
and intensive medical support. A repeat lactic acid with a concurrent
pyruvic acid revealed a lactic acid level of 26.0 mmol/L with a pyruvic
acid level of 0.34 mmol/L with a ratio of 76.5. Lactic acid levels contin-
ued to worsen and the decision was made to withdraw support. The
infant expired at 54 h of life. An autopsy was declined; however, the
patient and her parents were enrolled in an exome sequencing study
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er who had a very similar history and died at three days of life. Previous
chromosome andmicroarray analysis of the deceased sibling were nor-
mal (Supplement Table 1).2.3. CMH000036
The fourth case was a 2-month-old female delivered at 32 week
gestation due to non-reassuring fetal heart tones. There was a prena-
tal history of severe oligohydramnios, maternal tobacco use, fetal in-
tracranial calciﬁcations and an intracranial cyst. At birth, APGAR
scores were 8 and 8 at one and ﬁve minutes, respectively. A true um-
bilical cord knot was noted. Following delivery the infant developed
respiratory distress requiring CPAP. The chest X-ray demonstrated
cardiomegaly and hazy lung ﬁelds. The ﬁrst arterial blood was
remarkable for a pH of 7.07 and base excess of −16. She had a lactic
acid level of 25 mmol/L and was started on a bircarbinate drip. Persis-
tent metabolic acidosis, hyperglycemia, cardiomegaly, and worsening
respiratory distress prompted transfer to our institution on day of life
two. An echocardiogram demonstrated hypertrophic cardiomyopathy
with almost complete obliteration of the left ventricular cavity. A
genetics consultation was obtained. Notable ﬁndings included a
prominent occiput, 11 ribs, spade-shaped hands, externally rotated
ﬂat feet, and an anteriorly placed anus. A paternal history of ﬁxed api-
cal cardiac defect and thrombosis was noted, but felt to be unrelated
to clinical presentation of the patient. An extensive metabolic
work-up was conducted, including pyruvate dehydrogenase activity
in ﬁbroblasts, which was normal. The hospital course was complicat-
ed by persistent acidosis, respiratory failure, necrotizing enterocolitis,
and encephalopathy. Despite extensive medical care the patient died
at twomonths of multiorgan failure and was given a clinical diagnosis
of hypertrophic cardiomyopathy of undetermined etiology. An autop-
sy without restrictions was performed within ten hours of death. Mi-
tochondrial enzyme studies were performed post mortem on muscle
in a clinical laboratory (CIDEM), revealing deﬁciency in complexes I
and III that met a minor criterion for the diagnosis of a mitochondrial
respiratory chain disorder. In addition, there was increased citrate
synthase activity, suggestive of mitochondrial proliferation. Major
autopsy ﬁndings included left side hypertrophic cardiomyopathy,
chronic lung disease associated with prematurity and therapeutic
ventilatory assistance, cholestatic liver disease probably associated
to total parenteral nutrition, and chronic renal tubular disease sug-
gestive of smoldering tubular necrosis. A detailed description of the
autopsy ﬁndings is available in the Supplementary data. The underly-
ing cause of death was reported as premature birth with neonatal
diabetes mellitus syndrome and the immediate cause of death was
chronic lung disease of prematurity and myocardial hypertrophy of
different putative metabolic and nonmetabolic etiologies. The mecha-
nism of death was multiorgan failure with a possible contributing
condition of a persistent metabolic syndrome associated with
mitochondrial dysfunction of unknown molecular cause. Multiple ge-
netic tests for mitochondrial disorders were found to be unrevealing
(Supplement Table 1).Table 1
Exome sequencing summary.
CMH000067 CMH000068 CMH000069 C
Nucleotides sequenced 7,713,870,556 6,052,535,494 6,218,145,396 9
Mean nuclear coverage 59.6 48 47.5 6
Median nuclear coverage 50 40 40 5
Nuclear target w/ 10× coverage 90.56% 88.05% 88.52% 8
Mean mtDNA coverage 25.5 13.4 18.2 1
Median mtDNA coverage 25 13 18 1
mtDNA target w/ 10× coverage 99.06% 81.60% 95.69% 93. Results
Exome enrichment and sequencing on an Illumina HiSeq 2000 was
performed on CMH000067 and her two healthy parents (CMH000068
& CMH000069). The exome sequencing of CMH000067 generated a
total of 7.7 gigabases of sequence resulting in a mean nuclear exome
coverage of 59.6× and 86.0% of exome targets were covered at 16×
or greater (Table 1), a suitable value for accurate heterozygous variant
genotyping. Sequencing reads were aligned using GSNAP [8] and only
unambiguous, uniquely aligned reads which aligned best to a single lo-
cation in the nuclear or mitochondrial genome were evaluated for var-
iant calls. Despite nuclear exome enrichment, the mitochondrial
genome remained present and was sequenced concomitantly to an av-
erage depth of 25.5× resulting in 99.06% covered at 10× or greater
(Table 1). The parental exomes were sequenced to >6 gigabases and
had 88.05% and 88.52% of nuclear exome targets and 81.6% and
95.69% mtDNA covered at 10× or greater respectively (Table 1). A
total of 105,487 variants including 10 mtDNA variants were discovered
in CMH000069. Analysis revealed an apparently homoplasmic de novo
mutation in mtDNA 8993T>G (c.467T>G, p.Leu156Arg) in the ATP
synthase 6 gene (MT-ATP6, OMIM #516060; Fig. 2A). The variant was
seen in 21 of 21 sequencing reads covering the base. This is a known
disease causing variant responsible for 10–20% of Leigh syndrome
(OMIM #256000) cases due to deﬁcient activity of complex V (ATP
synthase) in the electron transport chain, however previous clinical se-
quencing of mtDNA in this patient did not include MT-ATP6 [9]. A clin-
ically validated restriction fragment length polymorphism (RFLP) assay
as well as capillary sequencing was used to conﬁrm these ﬁndings on
DNA from both blood and urine from the child (Fig. 2B). The
8993T>G mutation was not seen in maternal DNA from blood by
next-generation exome sequencing, but coverage (15×) was likely in-
sufﬁcient for the detection of low levels of heteroplasmy. Although the
8993 mutation is usually well-represented in blood [10], we tested
DNA isolated from both maternal urine and blood using capillary
sequencing and PCR/RFLP analysis. Although the mutation was
undetectable, these methods may fail to detect heteroplasmy of less
than 10%. Consequently, as most cases of Leigh syndrome due to the
8993 mutation are maternally inherited, we cannot rule out that the
mother may have a low level of heteroplasmy.
Exome sequencing was conducted on the proband (CMH000254),
her deceased sibling (CMH000255), and both parents. All samples
were sequenced to a depth of at least 8 gigabases resulting in greater
than 87% of the targeted regions receiving 10× or greater coverage
(Table 1). Less than 4% of the exome received 0× coverage. A total
of ~3500 variants for each sample were characterized as category
1–3 by RUNES (Supplement Table 2, [11]). Brieﬂy, category 1 variants
are those previously described as disease causing, category 2 are
those variants of the type likely to disrupt protein function and be dis-
ease causing if they are in a gene associated with disease and category
3 are variants of unknown signiﬁcance that may or may not cause dis-
ease. Filtering variants to exclude those present at an allele frequency
of >1% in the Center for Pediatric Genomic Medicine internal
database, which includes all variants ever detected from samples se-
quenced at the center and the corresponding frequency [11], resultedMH000254 CMH000255 CMH000256 CMH000257 CMH000036
,896,975,702 8,009,297,778 8,281,299,262 14,948,475,710 8,736,982,982
9.3 56.2 59.1 106.6 71.9
3 42 46 83 61
9.87% 87.48% 88.91% 92.56% 84.60%
7.6 59.4 19.9 31.8 30.1
7 57 19 32 30
0.37% 99.80% 92.53% 99.40% 99.22%
Fig. 2. Next-generation sequencing results viewed in the Integrative Genome Viewer [1] of mtDNA—8993T>G, MT-ATP6 in CMH000067 and maternal sample CMH000069.
MT-ATP6, 8993T>G is found in 21 of 21 reads (100% homoplasmy) in CMH000067 (A). Capillary sequencing conﬁrmation of the mtDNA—8993T>G mutation in DNA isolated
blood and urine from CMH000067 and her mother (B).
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Using a recessive inheritance model, variants were ﬁltered to only in-
clude homozygous variants or genes in which there were two or more
variants inherited on different alleles. Further ﬁltering of variants was
accomplished by limiting variants to those that were shared by both
affected siblings and resulted in a total number of 29 variants to in-
vestigate in 18 genes (Table 3). Of the 18 genes only six were associ-
ated with disease in OMIM, with NDUFV1 being the only gene
associated withmetabolism. Both infants were found to be compound
heterozygotes for two missense variants in the NDUFV1 gene
c.736G>A, p.Glu246Lys (Fig. 3A) and c.349G>A, p.Ala117Thr
(Fig. 3B). The parents each carry one variant, conﬁrming they are
present on opposite alleles. While neither variant has been previously
reported, both affect highly conserved codons and are predicted to be
damaging by in silico analysis. Furthermore, the Ala117Thr variant
has been found by clinical testing in addition to a second novel mis-
sense mutation in a patient with conﬁrmed mitochondrial disease
(personal communication—Renkui Bai). This genotype was interpreted
as being likely pathogenic and conﬁrmed clinically by capillary se-
quencing (Figs. 3A & B). NDUFV1 encodes a 464 amino acid long protein
that functions to release electrons from NADH via complex 1 of the
electron transport chain, with resultant movement of the electrons to
ubiquinone. The protein contains NADH, ﬂavin mononucleotide
(FMN) and iron–sulfur cluster binding sites that are predicted to be
necessary for proper functioning of complex I. The Glu246Lys mutation
occurs in the FMN binding site and could potentially be involved in
binding of NADH [12].
DNA isolated from peripheral blood cells from CMH000036 was
enriched for the nuclear exome and sequenced to 8.7 gigabases, pro-
ducing mean target nuclear exome coverage of 71.9× and mtDNA
coverage of 30.1× (Table 1). A total of 150,740 nuclear and 32
mtDNA variants were found. Of these variants 3242 were classiﬁed
as category 1–3 by RUNES [11] (Table 2). Applying a variant ﬁlter of
less than 1% frequency in our internal database reduced the number
of variants to 790. Due to lack of parental samples all genes withTable 2
Number of variants categorized as 1–3 by RUNES. category 1, previously described as
disease causing; category 2, of the type likely to disrupt protein function, category 3,
variant of unknown signiﬁcance; AF, allele frequency in CMH internal database of
greater than 1400 samples.
Cat. 1
total
Cat. 1
AF b1%
Cat. 2
total
Cat. 2
AF b1%
Cat. 3
total
Cat. 3
AF b1%
CMH000254 27 9 335 28 3113 393
CMH000255 31 14 346 28 3039 402
CMH000256 25 6 348 26 3170 412
CMH000257 33 14 346 28 3053 400
CMH000036 33 16 298 47 2911 727homozygous variants and genes with two or more variants were con-
sidered to be consistent with a recessive inheritance pattern, which
limited the total variants to 141 in 67 genes. Of these variants, three
were categorized 1 (Table 3) as previously reported disease causing
mutations including c.437G>A (Ser146Asn) in coenzyme Q2 homo-
log, prenyltransferase (COQ2) [13]. The c.437G>A mutation was
seen in 41 of 63 reads covering the position (Fig. 4A). Mutations in
COQ2 have been reported to cause coenzyme Q10 deﬁciency (OMIM
#609825) [13]. Further analysis of variants in COQ2 revealed a second
variant c.1159C>T present in 14 of 30 sequencing reads (Fig. 4B),
which causes an arginine to change to a premature stop codon at
amino acid position 387 (Arg387X). Taken together, these variants
in combination with the clinical phenotype are consistent with a di-
agnosis of coenzyme Q10 deﬁciency. In addition, we found a novel
variant (3754C>A) in the mitochondrial genome-encoded NADH de-
hydrogenase subunit 1, MT-ND1 gene (Supplement Fig. 1). This vari-
ant was found in 8 of 36 sequence reads aligned to this nucleotide
in the mitochondrial genome, implying ~22% heteroplasmy in periph-
eral blood. The variant was not found in more than 1400 other sam-
ples sequenced at CMH and was not reported in MitoMap [14],
suggesting it to be a novel variant. Unfortunately, a sample from the
mother could not be obtained. Subunit 1 is one of seven mtDNA
encoded subunits included among the approximately 41 polypep-
tides of respiratory complex I [15]. Mutations in MT-ND1 cause a
wide range of disorders, including Leber optic atrophy (OMIM
#535000) [16,17], mitochondrial complex I deﬁciency (OMIM
#252010) [18] and MELAS (OMIM #540000) [19]. Subsequent capil-
lary sequencing of DNA isolated from the blood, lung, and heart con-
ﬁrmed the 3754C>A mutation and was estimated to be ~25%
heteroplasmic on the basis of relative dideoxynucleotide peaks (Sup-
plement Fig. 2).4. Discussion
Genomic medicine, empowered by whole exome and whole ge-
nome sequencing, has been widely heralded as potentially transfor-
mational for medical practice [20–23]. Many of the early successes
of genomic medicine have come from monogenic disease discovery
[24–26] and diagnosis [11,27,28], particularly in disorders that fea-
ture clinical and genetic heterogeneities. Mitochondrial diseases
have both types of heterogeneity. Clinical features are often shared
between multiple diseases making it difﬁcult to arrive at a singular
clinical diagnosis. Furthermore, mitochondrial disease may be
inherited either as mutations in nuclearly encoded genes or in a
homoplasmic or heteroplasmic manner with the respect to the mito-
chondrial genome. These attributes greatly complicate accurate diag-
nosis of individuals suspected to have one of these disorders. Herein
Table 3
Number of variants and (genes) within RUNES categories 1–3 consistent with compound heterozygous inheritance.
Shared cat. 1 comp. het Shared cat. 2 comp. het Shared cat. 3 comp. het Cat. 1 comp. het Cat. 2 comp. het Cat. 3 comp. het
CMH000254 2 (1) 0 29 (18) CMH000036 3 (3) 13 (11) 125 (53)
CMH000255 2 (1) 0 29 (18)
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diagnosis after none were identiﬁed using conventional methods.
The diagnosis of Leigh syndrome (LS, OMIM #256000) in
CMH000067 was made through the identiﬁcation of an apparently
homoplasmic known disease-causing mutation (8993T>G) in
MT-ATP6. Although whole exome sequencing is not normally needed
to detect this speciﬁc variant, the fact that MT-ATP6 gene sequencing
had not been included in the more than 30 genes clinically sequenced
exempliﬁes the difﬁculty in ordering clinical sequencing for mitochon-
drial disorders. LS is an early-onset progressive neurodegenerative disor-
der with a characteristic neuropathology consisting of focal, bilateral
lesions in one or more areas of the central nervous system, including
the brainstem, thalamus, basal ganglia, cerebellum, and spinal cord.
The lesions are areas of demyelination, gliosis, necrosis, spongiosis, or
capillary proliferation. Clinical symptoms depend on which areas of the
central nervous system are involved. The most common underlying
cause is a defect in oxidative phosphorylation [29]. About 50% of children
with LS die by 3 years of age; however, clinical progression can be vari-
able and long-term outcomes cannot be predicted based on genotype
alone. For example, in individuals harboring the 8993T>G mutation,
higher 8993G heteroplasmy is often associated with LS while moderate
heteroplasmy is associated with less severe manifestations (weakness
with ataxia and retinitis pigmentosa (NARP)) [30,31]. While there is no
cure for LS, there are treatments that may improve cellular energetics.
Obtaining a deﬁnitivemolecular diagnosis allowed for improvedmedical
management for this patient by the patient's treating physician, includ-
ing the administration of sodium bicarbonate for chronic lactic acidemia,
treatment of seizures with antiepileptic medications, and carnitine
supplementation to aid excretion of abnormal byproducts of oxidative
phosphorylation [32,33].
Respiratory chain deﬁciencies have been increasingly recognized
in individuals presenting with a wide range of clinical problems,
including encephalopathy, intransigent lactic acidemia and early
death [34]. The electron transport chain consists of four membrane
associated complexes that function to ultimately provide reducing
substances for oxidative phosphorylation of ADP by ATP synthase
(complex V). Approximately 30% of respiratory chain disorders are
caused by deﬁciency of complex I, the largest complex of theFig. 3. Next-generation and capillary sequencing of variant c.736G>A (p.Glu246Lys) inherit
and CMH000257 (father) (A) and of variant c.349G>A (p.Ala117Thr) inherited from motherespiratory chain [6,12]. Complex I is a multi-subunit complex of
which 7 are encoded by mitochondrial DNA and at least 38 are
encoded by nuclear DNA. It functions to channel electrons from
NADH to ubiquinone and has, in addition to an NADH binding site, a
ﬂavin mononucleotide and Fe\S binding sites. NDUFV1 is a core
subunit of complex I and is necessary for catalytic activity. To date,
seventeen distinct mutations in the gene NDUFV1 have been de-
scribed (Supplement Table 3) with clinical effects ranging from
early infantile death to more classic features of Leigh syndrome.
CMH000254 and CMH000255 presented with fulminate metabolic
acidosis and lactic acidemia complicated by a neonatal encephalopa-
thy which was highly suggestive of an inborn error of energy metab-
olism. Using this information to direct analysis of sequence data
generated by exome sequencing, we were able to identify two muta-
tions in the NDUFV1 gene, c.349G>A(A117T) and c.736G>A(Q246K),
both of which are predicted to be deleterious by SIFT and/or
PolyPhen2 conservation analysis models. These mutations have only
been found in this family within the CMH variant database that hous-
es data from over 1400 patients sequenced. These changes were con-
ﬁrmed by capillary sequencing in both affected infants and their
parents. The mother is heterozygous for the c.349G>A(A117T) variant
while the father carries the c.736G>A(Q246K) change, conﬁrming
they were present on opposite alleles in the affected offspring. While
in vitro studies have not been completed, these variants are similar to
other known mutations in the NDUFV1 gene. NDUFV1 is a core subunit
in the N module of complex I. The N module functions as the electron
input module and has ﬂavin mononucleotide (FMN) as well as Fe\S
clusters. This module binds NADH and oxidizes it, resulting in the trans-
fer of electrons via FMN to the Fe\S clusters. Electrons are then trans-
ferred from the N module to the Q module which transfers them to
ubiquinone. The complex also includes a P module which translocates
protons across the membrane [35]. Several mutations (E214K, Y204C,
C206G) have been predicted to possibly disrupt FMN binding with re-
sultant decreased electron transfer, while others (A211V, A341V,
R257Q, R386C, T423M) affect NADH-quinone oxidoreductase, chain F
[35,36]. In our patients, one amino acid change is found proximal to res-
idues felt to be involved in FMN binding while the second is near resi-
dues predicted to be involved in oxidoreductase activity. This coulded from father in CMH000254 (proband), CMH00255 (sibling), CMH000256 (mother)
r (B) viewed in the Integrative Genome Viewer [1,50].
Fig. 4. Next-generation sequencing results viewed in the Integrative Genome Viewer [1] of variant c.437G>A (p.Ser146Asn) in COQ2 in CMH000036 found in 41 of 63 reads (A).
Next-generation sequencing results of variant c.1159C>T (p.Arg387X) in COQ2 in CMH000036 found in 14 of 30 reads (B).
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transfer and resultant deﬁciency of energy production in combination
with diminished oxidoreductase activity.
In the last patient, CMH000036, we were able to diagnose the pa-
tient with coenzyme Q10 deﬁciency due to two mutations in COQ2.
Similar to previous reports of COQ2 mutations our patient exhibited
oligohydramnios and renal disease. In addition, we also discovered
an apparently heteroplasmic variant inMT-ND1 (3754C>A). This var-
iant was novel in our internal database of greater than 1400 se-
quenced individuals and has not been reported in MitoMap [14].
Previous case reports of patients with MT-ND1mutations exhibit sig-
niﬁcant overlap with the clinical features seen in CMH000036 and are
consistent with the severe manifestations [32,33]. Lacking viable tis-
sue from the patient for functional studies or access to a maternal
sample, we used the scoring system for determining the pathogenic-
ity of mtDNA variants established by Mitchell and colleagues [37],
which puts signiﬁcant weight on heteroplasmy, conservation of the
residue (Supplement Fig. 3), and demonstration of a biochemical de-
fect in affected tissues. The 3754C>A variant scores in the 18–21
range, which is in the high possible/low probable range for being
pathogenic. Additional functional studies, such as mitochondrial
cybrid studies are needed to conﬁrm the pathogenicity of this variant.
As such, this variant is considered a variant of unknown signiﬁcance.
Importantly, it was detectable in the heteroplasmic state without spe-
ciﬁcally targeting the mitochondrial genome, highlighting the poten-
tial of exome sequencing to detect this type of pathogenic variant. We
are unable to completely rule out the possibility that CMH000036 had
two distinct disorders, CoQ10 deﬁciency and one of the disorders
associated with MT-ND1 mutations such as Leber optic atrophy
(OMIM #535000) [16,17], mitochondrial complex I deﬁciency
(OMIM #252010) [18] or MELAS (OMIM #540000) [19]. However,
we feel that it is highly likely due to the severity of the phenotype
that the CoQ10 deﬁciency was the primary cause of the clinical
phenotype caused by the mutations in the COQ2.
While the identiﬁcation of pathogenic changes in these patients
did not result in signiﬁcant changes in management or outcome, in
the future, early identiﬁcation of such conditions will likely play a
major role. In mitochondrial disorders in general, there is little
other than anecdotal evidence to support the use of therapies such
as carnitine, creatine, vitamins or bicarbonate. Conﬁrming that indi-
viduals have primary mitochondrial disorders could be the ﬁrst step
in developing thoughtful clinical trials of these compounds to assess
their efﬁcacy. For example, knowing that complex V ATPase activity
is diminished allows for the thoughtful addition of creatine as an al-
ternative source for the generation of GTP. In other cases, early diag-
nosis will allow for parents to make educated decisions about painful,
life-prolonging interventions that will ultimately prove futile. Know-
ing the recurrence risk is also important for those makingreproductive choices including the possibility of the identiﬁcation of
carrier status in biologically related individuals, prenatal diagnosis
in subsequent pregnancies or choosing different reproductive op-
tions, such as egg or sperm donor or adoption.
Several recent reports have demonstrated the efﬁcacy of next-
generation sequencing (NGS) for the diagnosis ofmitochondrial disorders
[27,38–40]. A panel that enriched ~1000nuclearmitochondrial genes and
themt genome identiﬁed known disease causingmutations in 24% of pa-
tients andnovel candidatemutations in an additional 31%of patientswith
mitochondrial phenotypes [27]. A separate study used a targeted ap-
proach to analyze nuclearly encoded mitochondrial genes and was able
to identify several pathogenic mutations in known genes as well as iden-
tifying novel candidate mutations and genes, yet did not analyze the
mtDNA in their study [38]. A beneﬁt of using deep NGS of the mtDNA is
the potential ability to detect lower levels of heteroplasmy and more ac-
curately impute the percentage of heteroplasmy. To this end, using a
targeted approach similar to Calvo et al. [27] allows for far greater depth
of coverage (e.g. >1000×) and sensitivity as compared to using a stan-
dard exome enrichment (~50×), but requires the use of a custom
targeted panel. Our ﬁndings clearly demonstrate the utility of using a
standard exome kit for examining the mtDNA and discovery of both
homoplasmic and heteroplasmic variants. However, in our experience
there aremultiple factors that affect the level of coverage obtained by tar-
get enrichment [22,24,41]. Speciﬁcally, we have observed, as reported by
others, that there is a difference in the coverage of the mtDNA given the
same amount of sequence using exome kits from different manufactures
(unpublished data, [39]). For example, in our lab more consistent and
deeper mtDNA coverage is obtained with Illumina exome kits as com-
pared to NimbleGen or Agilent, using DNA isolated from cell culture ver-
sus blood, using smaller targeted panels of ~2 megabases that do not
speciﬁcally target the mtDNA, and using different alignment algorithms
(unpublished data). Consequently, we recommend that the coverage of
themtDNA and the sensitivity and speciﬁcity of mtDNA variant detection
should be analyzed for each protocol and method used. In this study we
speciﬁcally chose to use Illumina exome enrichment because using our
methods we consistently obtain greater than 50× coverage of uniquely
aligning reads with 6 gigabases or more of sequencing, which allows for
analysis of both the nuclear andmtDNA genomes. It should be cautioned,
however, that there aremultiple limitations to next generation exome se-
quencing for clinical and molecular diagnostic purposes that we and
others have reported [22]. For example, many bioinformatic pipelines
are not well suited for detection of large insertions or deletions. The pipe-
line used in this manuscript cannot accurately detect insertions over
40 nts or deletions larger than 25 nts (Saunders et al., manuscript in
prep). Copy number variations are also not automatically detected, but
can be identiﬁed [41].
In conclusion, we show that the identiﬁcation of nuclearly-
encoded disease causing mutations and both homoplasmic and
155D.L. Dinwiddie et al. / Genomics 102 (2013) 148–156heteroplasmic mitochondrial variants may be detected using exome
sequencing without speciﬁcally enriching for mitochondrial sequences.
This is highly useful given the locus heterogeneity of mitochondrial
disorders that extends to two separate genomes. In both of these cases,
although mitochondrial disease was suspected, multiple diagnostic
tests failed to identify the molecular basis of the disease. The broad net
cast by exome and gene panel sequencing appears to be able to detect
cases of nuclearly [27] and potentiallymitochondrially-encoded diseases
[39,40], and is likely to offer a higher yield than testing small panels of
genes based on clinical or biochemical phenotype. We show in three
unrelated families, that exome sequencing can indeed be effective; how-
ever, we propose that additional studies to examine the speciﬁcity and
sensitivity in a larger number of samples are needed before it is consid-
ered as a primary diagnostic tool for patients with mitochondrial
diseases.
5. Methods
5.1. Consent
The study was approved by the Institutional Review Board of
Children's Mercy Hospital (CMH). Informed written consent was
obtained from all adult subjects and parents of living children.
5.2. Targeted exome sequencing
The Center for Pediatric Genomic Medicine (CPGM) at CMH
performed exome sequencing on a research basis. Isolated genomic
DNA was prepared for sequencing using the Kapa Biosystems library
preparation kit and 8 cycles of PCR ampliﬁcation. Exome enrichment
was conductedwith the Illumina TruSeq Exome v1 kit (62.2 megabases)
following a slightly modiﬁed version of themanufacturer recommended
protocol. The enrichment protocol was modiﬁed to use the Kapa
Biosystems PCR ampliﬁcation kit for the post-enrichment ampliﬁcation
step to limit polymerase induced GC-bias [42]. Successful enrichment
was veriﬁed by qPCR of 4 targeted loci and 2 nontargeted loci of the
sequencing library pre- and post-enrichment prior to sequencing [41].
The enriched library was sequenced on an Illumina HiSeq 2000 using
v3 reagents and 1 × 101 basepair sequencing reads.
5.3. Next generation sequencing analysis
Sequence data was generated with Illumina RTA 1.12.4.2 &
CASAVA-1.8.2, aligned to the human reference NCBI 37 using GSNAP
[8] and variants were detected and genotyped using GATK [43]. The
GATK Uniﬁed Genotyper discards reads with a low mapping quality
score so that only reads that aligned unambiguously to a single place in
the nuclear or mitochondrial genome were kept and analyzed [43]. We
have previously reported a high concordance of variants detected with
GSNAP/GATK and those detected using BWA/GATK [11]. Sequence
analysis employed FASTQ ﬁles, the compressed binary version of the
Sequence Alignment/Map format (bam, a representation of nucleotide
sequence alignments) and Variant Call Format (VCF, a format for nucle-
otide variants). Variants were characterized with the CPGM's Rapid Un-
derstanding of Nucleotide variant Effect Software (RUNES v1.0) [11].
RUNES incorporates data from the Variant Effect Predictor (VEP) soft-
ware [44], and produces comparisons to NCBI dbSNP, known disease
mutations from the Human Gene Mutation Database [45] and performs
additional in silico prediction of variant consequences such as the effect
of the variant on amino acid translation or splicing using ENSEMBL and
UCSC gene annotations [46,47]. RUNES categorizes each variant
according to the American College of Medical Genetics (ACMG's) recom-
mendations for reporting sequence variation [48,49] as well as an allele
frequency derived from CPGM's VariantWarehouse database [11]. Mito-
chondrial variants were further characterized by using mitoMap [13].5.4. Capillary sequencing
Primers and PCR conditions are available upon request. PCR prod-
ucts were puriﬁed using Exo-Sapit (USB Corporation, Cleveland, OH)
according to manufacturer's instructions. Both the forward and
reverse strands of the puriﬁed PCR product were sequenced using
ﬂuorescent dye-terminator sequencing. Sequencing reactions were
puriﬁed using the BigDye XTerminator Puriﬁcation Kit (Applied
Biosystems, Foster City, CA) according to the manufacturers' instruc-
tions. Results were analyzed on an ABI 3130 analyzer (Applied
Biosystems, Foster City, CA). Sequence results were compared to
published reference sequences using Sequencher 4.5 (Gene Codes
Corporation, Ann Arbor, MI).
5.5. Data and materials
The genomic sequence data for this study have been deposited in
the database dbGAP. Please contact authors for accession numbers.
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